Paloma Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-378
| Closed | -$91.9K | – | 1131 |
|
|
2024
Q2 | $91.9K | Sell |
378
-2,872
| -88% | -$453K | ﹤0.01% | 1087 |
|
|
2024
Q1 | $486K | Buy |
+3,250
| New | +$542K | 0.03% | 424 |
|
|
2023
Q4 | – | Sell |
-64
| Closed | -$11.3K | – | 730 |
|
|
2023
Q3 | $11.3K | Buy |
+64
| New | +$12.2K | ﹤0.01% | 658 |
|
|
2023
Q2 | – | Sell |
-531
| Closed | -$106K | – | 731 |
|
|
2023
Q1 | $106K | Buy |
+531
| New | +$112K | ﹤0.01% | 677 |
|
|
2022
Q4 | – | Sell |
-1,101
| Closed | -$220K | – | 903 |
|
|
2022
Q3 | $220K | Buy |
+1,101
| New | +$210K | 0.01% | 687 |
|
|
2021
Q4 | – | Sell |
-1,697
| Closed | -$320K | – | 1867 |
|
|
2021
Q3 | $320K | Buy |
+1,697
| New | +$318K | 0.01% | 694 |
|
|
2020
Q4 | – | Sell |
-43,141
| Closed | -$6.28M | – | 1606 |
|
|
2020
Q3 | $6.28M | Buy |
+43,141
| New | +$6.13M | 0.16% | 112 |
|
|
2020
Q1 | – | Sell |
-20,534
| Closed | -$2.37M | – | 1207 |
|
|
2019
Q4 | $2.37M | Buy |
+20,534
| New | +$2.05M | 0.04% | 517 |
|
|
2018
Q4 | – | Sell |
-3,956
| Closed | -$345K | – | 1242 |
|
|
2018
Q3 | $345K | Sell |
3,956
-6,429
| -62% | -$647K | 0.01% | 1171 |
|
|
2018
Q2 | $1.02M | Buy |
+10,385
| New | +$1.03M | 0.02% | 713 |
|
|
2018
Q1 | – | Sell |
-2,335
| Closed | -$297K | – | 1907 |
|
|
2017
Q4 | $297K | Sell |
2,335
-11,588
| -83% | -$1.46M | ﹤0.01% | 1557 |
|
|
2017
Q3 | $1.64M | Sell |
13,923
-9,055
| -39% | -$773K | 0.02% | 869 |
|
|
2017
Q2 | $1.83M | Buy |
22,978
+7,467
| +48% | +$477K | 0.02% | 816 |
|
|
2017
Q1 | $795K | Sell |
15,511
-10,027
| -39% | -$463K | 0.01% | 1371 |
|
|
2016
Q4 | $956K | Buy |
+25,538
| New | +$1.07M | 0.01% | 1207 |
|
|
2016
Q1 | – | Sell |
-11,900
| Closed | -$1.12M | – | 1835 |
|
|
2015
Q4 | $1.12M | Buy |
11,900
+8,360
| +236% | +$775K | 0.03% | 609 |
|
|
2015
Q3 | $284K | Sell |
3,540
-17,346
| -83% | -$1.93M | 0.01% | 1304 |
|
|
2015
Q2 | $2.5M | Buy |
20,886
+5,502
| +36% | +$658K | 0.05% | 365 |
|
|
2015
Q1 | $1.61M | Buy |
+15,384
| New | +$1.56M | 0.05% | 350 |
|
|
2014
Q4 | – | Sell |
-35,233
| Closed | -$2.75M | – | 1141 |
|
|
2014
Q3 | $2.75M | Sell |
35,233
-89,647
| -72% | -$5.78M | 0.13% | 161 |
|
|
2014
Q2 | $7.89M | Buy |
124,880
+120,940
| +3,070% | +$7.19M | 0.32% | 70 |
|
|
2014
Q1 | $265K | Buy |
+3,940
| New | +$305K | 0.02% | 527 |
|
|
2013
Q4 | – | Sell |
-4,271
| Closed | -$273K | – | 991 |
|
|
2013
Q3 | $273K | Buy |
+4,271
| New | +$213K | 0.01% | 682 |
|
Other funds holding ALNY
Paloma Partners's ALNY Position: Q3 2024 in Review
Paloma Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2024, closing a stake of 378 shares — an estimated $91.9K sold.
Paloma Partners first reported a position in ALNY in Q3 2013 and held it in 23 quarters. The position peaked at $7.89M in Q2 2014. 567 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.
- Paloma Partners reported no remaining Alnylam Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
- Paloma Partners sold 378 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $91.9K.
- Paloma Partners first reported a position in Alnylam Pharmaceuticals in Q3 2013 and held it in 23 quarters.
- Paloma Partners's Alnylam Pharmaceuticals position peaked at $7.89M in Q2 2014.
- 567 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.
Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.